

Study Of Ono 4538 In Unresectable Advanced Or Recurrent

This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.

This issue of Surgical Clinics of North America focuses on Gastric Neoplasms, and is edited by Drs. Douglas Tyler and Kelly Olinu. Articles will include: Minimally Invasive Surgical Approaches to Gastric Resection; The Management of GE Junction Tumors; Post-gastrectomy Syndromes and Nutritional Considerations Following Gastric Surgery; Surgical Considerations in the Management of Gastric Adenocarcinoma; The Evaluation and Management of Suspicious Gastric lesions following Bariatric Surgery; Post-surgical Surveillance for Gastric Adenocarcinoma; Neuroendocrine Tumors of the Stomach; Genetics of Gastric Cancer; The Management of Gastrointestinal Stromal Tumors; Endoscopic Management of Early Gastric Adenocarcinoma and Pre-Invasive Gastric Lesions; The Management of Non-Neoplastic Gastric Lesions; East Versus the West: Differences in Surgical Management in Asia Compared to Europe and North America; The Multimodality Approach to Gastric Lymphoma; The Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma; and more!

This volume focuses on the laboratory and clinical experience with targeting viral onco-antigens, while also reviewing the approaches to targeting self-cancer antigens in cancers of non-viral origin, where self-tolerance has been a challenge. It emphasizes the importance of selecting the right vaccine platform to induce a successful immune response against cancer antigens. In addition, the volume discusses the advances made with genetic vaccines, including recent advances with DNA vaccines and the rapid transition of mRNA vaccines from the laboratory to bedside. The new avenues opening up for cancer immunotherapy underline the importance of combinational approaches using cancer vaccines with costimulatory antibodies, which may dramatically improve cancer treatment. This book is intended for all translational researchers and clinicians who aspire to develop novel vaccination approaches for cancer patients with unmet clinical needs.

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today's best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. Features a new full-color design throughout, as well as updated diagnostic algorithms.

In Honor of Christoph Huber

From Mechanisms to Management

Free Radical Research in Cancer

Clinical Precision Medicine

This book provides a comprehensive overview of current immunotherapy strategies, and how these may be applicable to childhood cancers. The first part of the book reviews how the immune system recognizes cancer, and the various escape mechanisms allowing tumour growth. The importance of the tumor microenvironment and the challenges this may present to achieving effective immunotherapy are discussed. Monoclonal antibodies, cellular, cytokine and vaccine therapies are all comprehensively reviewed, with particular focus on their potential application to pediatric cancers. Practical aspects of delivering such therapies to children, likely toxicities and potential biomarkers are considered. Finally, consideration is given to how, in the longer term, such therapies may be combined with conventional therapies such as chemotherapy and radiotherapy. Edited by two distinguished pediatric oncologists with a collection of chapters from the most authoritative experts in cancer immunotherapy, this is an indispensable volume for pediatric oncologists and physicians working in childhood cancer care.

Advances in Immunology, a long-established and highly respected publication, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for the future. This volume focuses on tumor immunology. Contributions from leading authorities inform and updates on all the latest developments in the field

Drug Discovery in JapanInvestigating the Sources of InnovationSpringer Nature

Clinical Precision Medicine: A Primer offers clinicians, researchers and students a practical, up-to-date resource on precision medicine, its evolving technologies, and pathways towards clinical implementation. Early chapters address the fundamentals of molecular biology and gene regulation as they relate to precision medicine, as well as the foundations of heredity and epigenetics. Oncology, an early adopter of precision approaches, is considered with its relationship to genetic variation in drug metabolism, along with tumor immunology and the impact of DNA variation in clinical care. Contributions by Stephanie Kramer, a Clinical Genetic Counselor, also provide current information on prenatal diagnostics and adult genetics that highlight the critical role of genetic counsels in the era of precision medicine. Includes applied discussions of chromosomes and chromosomal abnormalities, molecular genetics, epigenetic regulation, heredity, clinical genetics, pharmacogenomics and immunogenomics Features chapter contributions from leaders in the field Consolidates fundamental concepts and current practices of precision medicine in one convenient resource

Pulmonary Adenocarcinoma: Approaches to Treatment

Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Drug Discovery in Japan

Cancer Immunotherapy Principles and Practice

Research and Clinical Applications of Targeting Gastric Neoplasms

Frontiers in Clinical Drug Research - Anti-Cancer Agents is an eBook series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The third volume of the eBook series begins with a detailed review of the molecular biology of inhibitors that target EGF-family receptors. This review is divided into two parts that cover extracellular and intracellular molecules. Other reviews cover targeted therapies for cancers such as melanoma, follicular lymphoma and topics such as cancer immunotherapy, apoptosis targeting and the Warburg Effect.

Get a quick, expert overview of the latest treatment and management approaches for adenocarcinoma of the lung, including novel therapeutics in immunotherapy and targeted therapies. This practical title, edited by Dr. Leon Horn, offers succinct coverage of clinically-focused topics and guidelines, making it an ideal resource for practicing and trainee oncologists and other members of the cancer care team.

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Now updated online for the life of the edition, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition keeps you up to date in this fast-changing field. Every quarter, your eBook will be updated with late-breaking developments in oncology, including new drugs, clinical trials, and more.

Immunotherapy in Cancer, An Issue of Hematology/Oncology Clinics of North America

Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer

Principles and Practice

Immuo-Oncology

IASLC Thoracic Oncology E-Book

This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.

Research and Clinical Applications of Targeting Gastric Neoplasms provides a comprehensive overview of gastrointestinal cancers, covering preclinical research and clinical findings related to risk factors, current treatment regimens (including immunotherapy), screening/detection methods, etiology of disease, precision medicine and future perspectives. Gastrointestinal cancers rank among the most lethal and common worldwide, and as such, there is intense research into their diverse causes and treatment options. This reference provides a consolidation of the research, making it a perfect resource for basic science and clinical researchers as well as oncologists who work in gastroenterology and GI tract cancer fields. Provides comprehensive coverage of preclinical research and the clinical aspects of gastric cancer Presents future perspectives from leading researchers in the field who provide the potential for furthering research topics Combines the expertise of researchers in GI tracts, cancer, immunity, immunology, infectious disease and microbiology for an interdisciplinary approach

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fifth volume of the book features reviews on biochemical inhibitors (second-generation protein kinase inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover cancers such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer.

This issue of Neurosurgery Clinics, guest edited by Dr. Mark H. Bilsky, will cover key topics in Spinal Oncology. This issue is one of four selected each year by our series consulting editors, Dr. Russell R. Lonser and Dr. Daniel K. Resnick. Topics discussed in this issue will include: Radiation Strategies for Chordoma, New Prospects for Molecular Targets in Chordoma, Surgical Strategies for Chordoma, State of the Art Treatment for Giant Cell Tumors, NOMS and Other Decision Frameworks for Metastatic Disease, Evolving Role of SBRT in Spine Metastases, Hybrid Therapy for Metastatic Disease, Interventional Hybrid Therapy for Metastatic Disease LITT and SBRT, MIS Strategies Changing the Treatment of Spine Tumors, Intradural Tumors, SBRT for Benign Spine Tumors, and Evolving Diagnostic Treatment Paradigms for Spine and Peripheral Nerve Manifestations of NF, among others.

Prevention, Diagnosis and Therapy

Cancer Immunotherapy Meets Oncology

Advances in Esophageal and Gastric Cancers, An Issue of Surgical Oncology Clinics of North America E-Book

Immunotherapy for Pediatric Malignancies

Frontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 5

Over the last decade, immuno-oncology has witnessed an astonishing pace of discovery and innovation translating into unprecedented successes in the clinical setting, arguably representing one of the most profound and transforming revolution in the history of cancer therapy. This book provides a concise and accurate outline of the main developments in major tumor types including melanoma, lung, breast, brain and renal cell cancers. In addition, transversal chapters that describe the commonalities of some of the therapeutic strategies are provided to cover topics like immune checkpoint biology, T cell engineering or rational combination therapies. Each chapter has been authored by senior key opinion leaders in their respective fields to provide the most up-to-date view on cancer immuno-oncology. To reflect on the key translational aspect of immuno-oncology, all chapters are making explicit connections between basic science discoveries and the resulting translational therapeutic strategies. Immuo-Oncology will be an invaluable source of information for scientists interested in the translation of basic immunology into the clinical practice, as well as for clinician interested in deepening their knowledge of current and upcoming immune strategies in the fight against cancers.

Gastric cancer remains an important issue in the world of oncology. In 2013, it ranked fifth by global incidence and second by mortality. Really, it is true that the death rates have decreased significantly in the USA and in Europe over the 100-year period; meanwhile, gastric cancer can be characterized by poor prognosis and high mortality, with the exception of early diagnosed patients. Oncological (basic and clinical) research increased extremely in the last decades (including gastric cancer). The authors participating in this book are internationally well-known experts from 11 countries of the world, working in different fields of gastric cancer research, and they summarize the results obtained in the last years. The conclusions of these abovementioned observations fall between the findings of classical prospective, randomized, multiclinical, multinational (and meta-analyzed) generally accepted studies (in accordance with the presently applied and internationally accepted protocols) and the scientifically-based (however individual) molecular targeting organ therapies. The book gathers experts in basic science, molecular pharmacologists, biochemical pharmacologists, basic and clinical oncologists, internists, surgeons, gastroenterologists, tumor pharmacologists as well as experts working in the field of oncology.

Lung cancer is the most common cause of death from cancer worldwide – it is estimated to cause nearly one in five cancer deaths. Most lung cancer patients are diagnosed late and for many of them, there are currently no curative therapy options available, meaning long-term survival is still low. Nevertheless, enormous progress has been made in the field during the last decade. This Monograph provides a comprehensive overview of the current knowledge of and advances in lung cancer, covering areas such as: screening; tobacco control; COPD; diagnosis; therapy; and treatment of early stage lung cancer from both a surgeon's and radiation oncologist's perspective. Very recent achievements in innovative fields, such as targeted therapies and immunotherapies, are also discussed. New developments in molecular biology have led to an explosive growth in the knowledge underlying mechanisms of carcinogenesis: cell signalling, tumor progression and development of metastasis. However, cure of cancer is still hampered by the inherited capacity of tumors to become resistant to standard therapies, to metastasize from their initial location and to proliferate in other tissue compartments. Radiotherapy is one of the main treatment modalities to achieve locoregional tumor control. However, the treatment of distant metastases further remains to be a challenge. In this special topic we are interested to elucidate immunological aspects which are initiated and affected by radiotherapy. We also aim to describe the development of innovative immunological strategies from a preclinical stage to clinical application which could be combined with standard radiotherapeutic approaches. A special interest will also deal with the effects of radiotherapy on tumor initiating cells as well as on the tumor microenvironment. Last but not least the effects of different irradiation sources and qualities such as photons, protons and heavy ions will be analyzed with respect to immunological outcome.

Liver Cancers

Sensitization and Desensitization in Organ Transplantation

Development and Potential Mechanisms of Low Molecular Weight Drugs for Cancer Immunotherapy

Inflammation and Lung Cancer

Melanoma

The second edition of this very successful book documents the latest progress in the prevention, diagnosis and treatment of esophageal cancer and includes additional sections covering novel targeted therapeutic approaches, immunotherapy and palliative and nutritional support for patients. Furthermore, the sections covering epidemiology, molecular biology, pathology, staging and radiologic and endoscopic assessments have been thoroughly updated and expanded. The principles of surgical resection, radiation therapy and systemic therapy are reviewed and attention is paid to the multidisciplinary approaches to the management of early stage cervical, thoracic, distal and junctional tumors. Updated information is also provided on the treatment of metastatic and recurrent disease as well as approaches that may impact future care, such as chemoprevention. Esophageal Cancer: Prevention, Diagnosis and Therapy will assist specialists from various disciplines, including surgery, radiation therapy, gastroenterology, medical oncology and palliative medicine, in delivering optimal, up-to-date care to the benefit of patients.

In recent years there have been various discoveries connecting inflammation and lung cancer and clearly there is growing interest in this area of cancer research. The link between unresolved inflammation and cancer has been well established with estimates that 15% of cancer deaths are inflammation-related. Evidence for this link includes the following: a) some inflammatory diseases are associated with increased risk of cancer development; b) inflammatory mediators are present surrounding and within most tumors; c) overexpression of inflammatory cytokines increases cancer development and progression in murine studies; d) inhibition of inflammatory mediators decreases cancer development and progression; and e) the use of nonsteroidal antiinflammatory drugs (NSAIDs) has been found to decrease cancer incidence and delay progression. The volume will present aspects of the inflammatory tumor microenvironment (TME), its many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of microRNAs (miRNAs) and an increase in a stem cell phenotype. The book will also cover the mechanisms of inflammatory mediators. Chronic overexpression of inflammatory mediators in the TME, as seen in smokers and patients with non?small cell lung cancer (NSCLC), can also lead to increased tumor initiation, progression, invasion and metastasis. The volume will provide a comprehensive perspective of the latest findings and summaries of progress made regarding inflammation and its connection to lung cancer.

This issue of Thoracic Surgery Clinics of North America focuses on Pulmonary Metastasectomy. Articles will include: Biology of Pulmonary Metastases; Preoperative Evaluations and Indications for Metastasectomy; Open Approaches to Pulmonary Metastases: Thoracotomy and Sternotomy; Ablative Approaches for Pulmonary Metastases: RFA, microwave, SBRT; Role of Lymphadenectomy with Pulmonary Metastasectomy; Results of Pulmonary Resection: Colorectal Carcinoma; Results of Pulmonary Resection: Sarcoma and Germ Cell Tumors; Isolated Lung Perfusion; Immunotherapy; Medical Management of Pulmonary Metastases: Is There a Role for Surgery?; Thoracoscopic Management of Pulmonary Metastases; Results of Pulmonary Resection: Other Epithelial Malignancies; Thoracoscopic Lung Suffusion; and more!

Topics in Anti-Cancer Research covers important advances on both experimental (preclinical) and clinical cancer research in drug development. The book series offers readers an insight into current and future therapeutic approaches for the prevention of different types of cancers, synthesizing new anti-cancer agents, new patented compounds, targets and agents for cancer therapy as well as recent molecular and gene therapy research. The comprehensive range of themes covered in each volume will be beneficial to clinicians, immunologists, and R&D experts looking for new anti-cancer

targets and patents for the treatment of neoplasms as well as varied approaches for cancer therapy.

Pulmonary Metasectomy, an Issue of Thoracic Surgery Clinics of North America

Frontiers in Clinical Drug Research – Anti-Cancer Agents

Evidence-based Advance and Management of Adverse Events of Immunotherapy for Cancer

Spinal Oncology An Issue of Neurosurgery Clinics of North America

Gastric Cancer

Cancer is a great challenge to efficient therapy due to biological diversity. Disturbed oxidative homeostasis in cancer cells certainly contributes to differential therapy response. Further, one of the hallmarks of cancer cells is adaptation which includes fine tuning of the cellular metabolic and signalling pathways as well as transcription profiles. There are several factors which contribute to the tumour diversity and therapy response, and oxidative stress is certainly one of them. Changes in oxygen levels due to hypoxia/reoxygenation during tumor growth modulate antioxidant patterns finally supporting increased cell diversity and adaptation to stressing conditions. Additionally, cancer chemotherapy based on ROS production can also induce also adaptation. To counteract these negative effects natural products are often used for their antioxidant activities as well as photodynamic therapy supported by novel chemosensitizers. Understanding of possible pathways which can trigger antioxidant defence at a certain time during cancer development can also provide possible strategies in fighting cancer.

This issue of Hematology/Oncology Clinics, guest edited by Patrick A. Ott, will focus on Immunotherapy in Cancer. Topics include, but are not limited to, Cancer Vaccines, Innate Immune stimulation, Costimulatory and Agonistic Antibodies, Immune modulation with radiation, Oncolytic virus therapy, Cytokine Therapy, Adoptive T cell transfer, Immune related toxicity, and Immune checkpoint combinations.

Melanoma is one of the most types of cancer. When melanoma is detected at an early stage, treatment is highly successful, but outcomes can be poor when the disease is advanced. There has been significant progress in our understanding of the molecular biology, genetics, and immunology of melanoma over the past decade. This has been accompanied by rapid advances in therapeutic strategies for patients with melanoma. This book provides the clinician and the researcher with a broad understanding of the molecular and cellular pathogenesis of melanoma, explores the clinical characteristics and criteria for clinical and pathological staging of the disease, and provides an overview of current and evolving treatment strategies in the adjuvant, metastatic, and preventive settings. The treatment of special populations and rare variants of melanoma that often present particular clinical challenges is also covered. Authored by international experts in melanoma biology and clinical management, this volume concisely explains how to diagnose, treat, and prevent melanoma while reviewing advances in basic science and providing an overview of innovative approaches still under development.

Lung cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we've started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalog our current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists: we finally feel sense optimism about treatment options for our patients.

Challenging Concepts in Oncology

Kidney Cancer

Investigating the Sources of Innovation

Lung Cancer

A Primer

Cancer Immunotherapy Principles and Practice, from the Society of Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation. This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject. Key Features: Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations Includes expert perspectives from leading authorities in the field Provides information on all FDA-approved immunotherapies, including clinical management and outcome data Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies. Explains regulatory aspects behind the development and approval of immunotherapy drugs Includes Online Access to the Digital Book

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. David Ilson, is devoted to Topics in Esophageal and Gastric Cancers. Dr. Ilson has assembled expert authors to review the following topics: Minimally Invasive Surgery: The Emerging Role in Esophageal and Gastric Cancer; Novel Targeted Therapies in Esophagogastric Cancer; The Role of Nutritional Support in Esophagogastric Cancer; Screening and Preventive Strategies in Esophagogastric Cancer; Current Progress in HER2 Targeted Therapies in Esophagogastric Cancer; The Role of Radiotherapy in Esophagogastric Cancer; Endoscopic Management of Early Esophagogastric Cancer; Current Progress in the Adjuvant Treatment of Gastric Cancer; Controversies and Consensus in Preoperative Therapy of Esophageal and GE Junction Cancers; Issues in the Management of Esophagogastric Cancer in Geriatric Patients; East versus West: The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer; The Current Status of Immunotherapies in Esophagogastric Cancer; and more!

This issue of Hematology/Oncology Clinics will focus on Upper Gastrointestinal Malignancies; specifically, articles on the following: Epidemiology / Genetics, H. pylori and the gastric microbiome in gastric cancer carcinogenesis; Barrett 's esophagus and esophageal cancer; Tumor Staging; Localized disease; Metastatic Disease; Immunotherapy Antiangiogenic therapy; and many more!

Kidney Cancer: Principles and Practice is a comprehensive and interdisciplinary textbook that encompasses all clinically relevant aspects of the disease. This new edition has been extensively updated and includes brand new material covering the most recent developments in kidney cancer diagnosis and therapy. The user-friendly and clinically oriented content of the book guarantees that it will be of great interest to a wide range of medical professionals, and every effort has been made to ensure that contributions are both easy to understand and directly related to patient care. Content presentation departs from the usual dense chapter format featuring a lengthy series of paragraphs. Instead, each chapter contains several boxed sections, including one that summarizes essential "take home points" for the busy clinician and another that presents a patient-oriented case highlighting the clinical application of elements discussed in that chapter. In addition, accessible original images, illustrations, and diagrams (some in full color) are used to simplify particularly complex material. This book will be of value for clinicians, researchers, residents, fellows, students, and knowledgeable lay people. The contributors comprise an international group of authors with expertise in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others.

Upper Gastrointestinal Malignancies, An Issue of Hematology/Oncology Clinics of North America E-Book

Multidisciplinary Management of Gastric Neoplasms, An Issue of Surgical Clinics, E-Book

Immu-Related Adverse Events for Patients with Lung Cancer

Treatment and Research

Radiation-induced effects and the immune system

Providing the inside track on how the experts approach and deal with real-world clinical scenarios, Challenging Concepts in Oncology contains wide-ranging and in-depth reviews of contemporary and often contentious topics in the world of oncology today. With a case-based approach and expert commentary throughout, complex patient presentations are discussed from a multidisciplinary perspective and all the angles necessary for accurate assessment, diagnosis, and management are fully considered and explored. Each case contains 'Clinical Tips', 'Learning Points', 'Expert Comments' and 'Evidence Base' to enhance the learning process and provide easy reference to important supplementary material. Aimed primarily at specialty trainees and registrars in oncology, this text will appeal to all those healthcare professionals with an interest in oncology.

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusingogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

This book explores in detail the primary liver cancers of hepatocellular carcinoma and cholangiocarcinoma examining the pathogenesis of disease along with diagnosis and current management options together with exploration of future treatment strategies and areas of controversy. Furthermore, the book highlights management of the common secondary malignancies and touches on benign liver tumours and how to best manage these. Written in a clear and didactic style, this volume includes summaries of the key learning points and questions so that the reader can gauge their knowledge and understanding. This book is aimed to broaden the knowledge base of primary care physicians, general physicians along with specialists in hepatology, oncology and hepato-biliary surgery

DeVita, Hellman, and Rosenberg's Cancer

Esophageal Cancer

Topics in Anti-Cancer Research

Tumor Immunology

Advances in the Molecular Mechanisms in Gastrointestinal Tumorigenesis and Treatment